prescribing safety assessment MCQ (SBA): Benign Prostatic Hyperplasia

Instant feedback + full explanation. One question, done properly.

MediumPharmacologyBenign Prostatic Hyperplasiaprescribing safety assessmentmrcgp aktukmla

A 78-year-old man with known benign prostatic hyperplasia (BPH) is prescribed oxybutynin for overactive bladder symptoms. What is a significant potential adverse effect related to his BPH that the prescriber should be particularly cautious about?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

prescribing safety assessment MCQ: Benign Prostatic Hyperplasia — Answ